Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
IUBMB Life. 2019 Oct;71(10):1428-1441. doi: 10.1002/iub.2108. Epub 2019 Jul 19.
Colorectal cancer (CRC) is one of the most common malignancies with poor prognosis. Oxaliplatin-based chemotherapy is an important treatment for CRC; however, the cells develop resistance to therapy. The mechanisms underlying oxaliplatin resistance are complex and unclear. There is increasing evidence that microRNAs (miRNAs) (i.e., miR-34a, miR-143, miR-153, miR-27a, miR-218, and miR-520) play an essential role in tumorigenesis and chemotherapy resistance, by targeting various cellular and molecular pathways (i.e., PI3K/Akt/Wnt, EMT, p53, p21, and ATM) that are involved in the pathogenesis of CRC. Identifying the miRNAs that are involved in chemo-resistance, and their function, may help as a potential therapeutic option for treatment of CRC or as potential prognostic biomarker. Here, we summarized the clinical impact of miRNAs that have critical roles in the development of resistance to oxaliplatin in CRC.
结直肠癌（CRC）是预后不良的最常见恶性肿瘤之一。基于奥沙利铂的化疗是 CRC 的重要治疗方法；然而，细胞对治疗产生了耐药性。奥沙利铂耐药的机制复杂且不明确。越来越多的证据表明，microRNAs（miRNAs）（即 miR-34a、miR-143、miR-153、miR-27a、miR-218 和 miR-520）通过靶向参与 CRC 发病机制的各种细胞和分子途径（即 PI3K/Akt/Wnt、EMT、p53、p21 和 ATM），在肿瘤发生和化疗耐药中发挥重要作用。鉴定参与化疗耐药的 miRNAs 及其功能，可能有助于作为治疗 CRC 的潜在治疗选择或作为潜在的预后生物标志物。在这里，我们总结了在 CRC 中对奥沙利铂耐药性发展具有关键作用的 miRNAs 的临床影响。
